1.
Nicolò E, Gandini S, Giugliano F, et al. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials. European journal of cancer (Oxford, England : 1990). 2024;207:114181. doi:10.1016/j.ejca.2024.114181.
1.
Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888-898. doi:10.1182/blood-2017-08-802470.
1.
Edelman G, Rodon J, Lager J, et al. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018;23(4):401-e38. doi:10.1634/theoncologist.2017-0691.
1.
Kato N, Comer E, Sakata-Kato T, et al. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature. 2016;538(7625):344-349. doi:10.1038/nature19804.